Merz Therapeutics GmbH — Biomedical Watch V2

Traitements5programmes

Essais3liés

Publications4liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Levodopa inhalation powderParkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing. This study aims to explore the experiences of people with Parkinson's disease who are prescribed Inbrija® as part of their usual care. Through a mixed-methods approach, the study will examine how OFF episodes affect patients, what influences their decision to use Inbrija®, and whether patient-reported outcomes related to symptoms, daily functioning, and quality of life change during the first 3 months of treatment. The study is planned to be conducted at approximately 7 sites in Austria, Germany, and Sweden and will enroll up to 120 participants receiving Inbrija® in routine clinical practice.	Parkinson	À vérifier	Traitement symptomatique	Austria	À vérifier
XeominIn this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.	Migraine	Phase 3	À vérifier	United States, Austria, Canada, Czechia, Denmark, France, Germany, Italy, …	À vérifier
XeominIn this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.	Migraine	Phase 3	À vérifier	United States, Austria, Canada, Czechia, Denmark, France, Germany, Italy, Poland, Slovakia, Spain, Switzerland, United Kingdom	À vérifier
XeominIn this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.	Migraine	Phase 3	À vérifier	United States, Austria, Canada, Czechia, Denmark, France, Germany, Italy, Poland, Slovakia, Spain, Switzerland, United Kingdom	À vérifier
Levodopa inhalation powderParkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing. This study aims to explore the experiences of people with Parkinson's disease who are prescribed Inbrija® as part of their usual care. Through a mixed-methods approach, the study will examine how OFF episodes affect patients, what influences their decision to use Inbrija®, and whether patient-reported outcomes related to symptoms, daily functioning, and quality of life change during the first 3 months of treatment. The study is planned to be conducted at approximately 7 sites in Austria, Germany, and Sweden and will enroll up to 120 participants receiving Inbrija® in routine clinical practice.	Parkinson	À vérifier	Traitement symptomatique	Austria	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
Levodopa inhalation powder	Parkinson	À vérifier	NCT07797790	INHALE-PD — Real-world Patient Experiences With Inbrija®	RECRUITING
Xeomin	Migraine	Phase 3	NCT07018700	MINT-E — A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine	ACTIVE_NOT_RECRUITING
Xeomin	Migraine	Phase 3	NCT07018713	MINT-C — A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine	ACTIVE_NOT_RECRUITING

Publications

4

Molécule	Indication / population	Titre	Journal	Date
Levodopa inhalation powder		Review of levodopa inhalation powder (Inbrija) for Parkinson's disease.	Drug and therapeutics bulletin
Levodopa inhalation powder		Correction: .	Drug and therapeutics bulletin
Xeomin		Phenotype and Genetics of Spinocerebellar Ataxia Type 27B: Novel Movement-disorder Features, Cognitive Impairment, and Repeat Expansion Findings.	Cerebellum (London, England)
Xeomin		Botulinum Toxin Type A in Spasticity and Cervical Dystonia: Practical Clinical Recommendations from a Mexican Multidisciplinary Panel of Specialist Injectors.	Toxins